Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment.
Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment.
复制标题
DOI：
10.3390/biomedicines9121893
复制
发表时间：
2021-12-13
期刊：
影响因子：
4.7
通讯作者：
Li G
中科院分区：
文献类型：
--
作者：
Yang M;Khoukaz L;Qi X;Kimchi ET;Staveley-O'Carroll KF;Li G
非酒精性脂肪性肝病（NAFLD）的发病机制范围从非酒精性脂肪肝（NAFL）到非酒精性脂肪性肝炎（NASH）的晚期形式，影响全球约25%的人口。NAFLD是一种与肥胖、2型糖尿病和代谢综合征相关的慢性肝病，是导致肝细胞癌（HCC）的最常见因素。虽然在探索NAFLD的发病机制和治疗靶点方面取得了进展，但美国食品和药物管理局（FDA）尚未批准任何治疗药物。肠道微生物群衍生的组分和代谢产物在NAFLD或NASH进展期间形成肝内免疫中起关键作用。随着单细胞RNA测序（scRNA-seq）等技术的进步，人们对肝脏中免疫细胞的每种亚型进行了研究，以探索它们在NAFLD发病机制中的作用。此外，还发现了参与肠道微生物群介导的NAFLD影响的新分子。基于这些发现，我们首先总结了NAFLD发生和进展过程中饮食-肠道微生物群衍生代谢物与肝内免疫激活的相互作用。然后讨论了针对肠道微生物群和重要分子信号通路的治疗方案。最后，选择正在进行的临床试验来展示针对NAFLD或NASH的治疗的潜在应用。
Nonalcoholic fatty liver disease (NAFLD) with pathogenesis ranging from nonalcoholic fatty liver (NAFL) to the advanced form of nonalcoholic steatohepatitis (NASH) affects about 25% of the global population. NAFLD is a chronic liver disease associated with obesity, type 2 diabetes, and metabolic syndrome, which is the most increasing factor that causes hepatocellular carcinoma (HCC). Although advanced progress has been made in exploring the pathogenesis of NAFLD and penitential therapeutic targets, no therapeutic agent has been approved by Food and Drug Administration (FDA) in the United States. Gut microbiota-derived components and metabolites play pivotal roles in shaping intrahepatic immunity during the progression of NAFLD or NASH. With the advance of techniques, such as single-cell RNA sequencing (scRNA-seq), each subtype of immune cells in the liver has been studied to explore their roles in the pathogenesis of NAFLD. In addition, new molecules involved in gut microbiota-mediated effects on NAFLD are found. Based on these findings, we first summarized the interaction of diet-gut microbiota-derived metabolites and activation of intrahepatic immunity during NAFLD development and progression. Treatment options by targeting gut microbiota and important molecular signaling pathways are then discussed. Finally, undergoing clinical trials are selected to present the potential application of treatments against NAFLD or NASH.
登录
查看更多内容
影响因子：
29
作者：
Clifford BL;Sedgeman LR;Williams KJ;Morand P;Cheng A;Jarrett KE;Chan AP;Brearley-Sholto MC;Wahlström A;Ashby JW;Barshop W;Wohlschlegel J;Calkin AC;Liu Y;Thorell A;Meikle PJ;Drew BG;Mack JJ;Marschall HU;Tarling EJ;Edwards PA;de Aguiar Vallim TQ
通讯作者：
de Aguiar Vallim TQ
影响因子：
3.6
作者：
Charatcharoenwitthaya P;Kuljiratitikal K;Aksornchanya O;Chaiyasoot K;Bandidniyamanon W;Charatcharoenwitthaya N
通讯作者：
Charatcharoenwitthaya N
DOI：
10.1152/ajpgi.00040.2019
发表时间：
2020-02-01
影响因子：
4.5
作者：
Breuer, Denitra A.;Pacheco, Maria Cristina;Kennedy, Arion J.
通讯作者：
Kennedy, Arion J.
影响因子：
25.7
作者：
Drescher, Hannah K.;Schippers, Angela;Kroy, Daniela C.
通讯作者：
Kroy, Daniela C.
影响因子：
5
作者：
Bala, Shashi;Ganz, Michal;Babuta, Mrigya;Zhuang, Yuan;Csak, Timea;Calenda, Charles D.;Szabo, Gyongyi
通讯作者：
Szabo, Gyongyi